No, I do not think that manufacturing will move offshore from Canada. Gilead does a substantial amount of manufacturing in Canada because it's a great place to do business for manufacturing. We have high-quality manufacturing, great capabilities, and a very educated, skilled workforce here, so I think this will always be a good place to manufacture.
In India they've just been doing this for a long time. They haven't had patents, historically. They are now actually adopting the TRIPS requirement to enforce intellectual property, so I think it remains to be seen what impact that will have on the developing world for access to medicines.
As I mentioned in my testimony, I think that's an important role CAMR could play. If the availability of low-cost generics is cut off from India, that could be a good place for CAMR to provide a safeguard to ensure that patients still receive access to those medicines.
India has similar legislation in place as well, so my guess is that a lot of those countries in the developing world will go to India, even under a compulsory licence regime.